Short-term downward fluctuations or profit-taking phases affecting Axsome Therapeutics (NASDAQ: AXSM) are typically driven by routine market corrections, broader biotechnology sector rotations, or investor responses to periodic earnings reports. Because growth-stage biopharmaceutical equities experience high sensitivity to macroeconomic sentiment and clinical development timelines, temporary price pullbacks frequently occur after periods of significant upward scaling. However, the company's core commercial drivers, such as increasing prescription sales for its flagship central nervous system medications, continue to anchor long-term institutional interest.